



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT **(\\$)** **\$180.00**

Complete if Known

Application Number	10/657,570
Filing Date	September 8, 2003
First Named Inventor	Chandrakumar
Examiner Name	Not Assigned
Group Art Unit	Not Assigned
Attorney Docket No.	2927/1A

METHOD OF PAYMENT (check all that apply)

Check Credit card Money Order Other None

Deposit Account:

Deposit Account Number **19-1025**

Deposit Account Name **Pharmacia Corporation**

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Description	Fee Paid
Fee Code	Fee Code	Fee Description	
1051	130	2051 65 Surcharge - late filing fee or oath	
1052	50	2052 25 Surcharge - late provisional filing fee or cover sheet	
1053	130	1053 130 Non - English specification	
1812	2,520	1812 2,520 For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804 920* Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805 1,840* Requesting publication of SIR after Examiner action	
1251	110	2251 55 Extension for reply within first month	
1252	410	2252 205 Extension for reply within second month	
1253	930	2253 465 Extension for reply within third month	
1254	1,450	2254 725 Extension for reply within fourth month	
1255	1,970	2255 985 Extension for reply within fifth month	
1401	320	2401 160 Notice of Appeal	
1402	320	2402 160 Filing a brief in support of an appeal	
1403	280	2403 140 Request for oral hearing	
1451	1,510	1451 1,510 Petition to institute a public use proceeding	
1452	110	2452 55 Petition to revive - unavoidable	
1453	1,300	2453 650 Petition to revive - unintentional	
1501	1,300	2501 650 Utility issue fee (or reissue)	
1502	470	2502 235 Design issue fee	
1503	630	2503 315 Plant issue fee	
1460	130	1460 130 Petitions to the Commissioner	
1807	50	1807 50 Processing fee under 37 CFR § 1.17(q)	
1806	180	1806 180 Submission of Information Disclosure Statement	180.00
8021	40	8021 40 Recording each patent assignment per property (times number of properties)	
1809	750	2809 375 Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810 375 For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801 375 Request for Continued Examination (RCE)	
1802	900	1802 900 Request for expedited examination of a design application	

Other fee (specify) _____

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code (\$)	Fee Description	Fee Paid
1001	750	2001 375 Utility filing fee		
1002	330	2002 165 Design filing		
1003	520	2003 260 Plant filing fee		
1004	750	2004 375 Reissue filing		
1005	160	2005 80 Provisional filing fee		
SUBTOTAL (1) (\\$)				

2. EXTRA CLAIM FEES FOR UTILITY AND

Extra Claims	Fee from below	Fee Paid
Total Claims	-20** = 0	X 0 = 0.00
Independent Claims	-3** = 0	X 0 = 0.00
Multiple Dependent		= 0.00

Large Entity	Small Entity	Fee Description
1202	18	2202 9 Claims in excess of 20
1201	84	2201 42 Independent claims in excess of 3
1203	280	2203 140 Multiple dependent claim, if not paid
1204	84	2204 42 ** Reissue independent claims over original patent
1205	18	2205 9 ** Reissue claims in excess of 20 and over original patent
SUBTOTAL (2) (\\$)		\$0.00

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) **(\\$) \$180.00**

**or number previously paid, if greater; For Reissues, see above


SUBMITTED BY

Name (Print/Type)	Rachel A. Polster	Registration No. (Attorney/Agent)	47,004	Telephone	314-274-7354
Signature	<i>Rachel A. Polster</i>		Date	December 11, 2003	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



CERTIFICATE OF MAILING BY FIRST-CLASS MAIL (37 CFR 1.8)

Serial No: 10/657,570

Filing Date: September 8, 2003

Group Art Unit: Not Assigned

Docket No: 2927/1A

Invention: Meta-Substituted Phenylene Sulphonamide Derivatives

Date of Deposit: December 11, 2003

I hereby certify that these papers or fee is being deposited with the United States Post Office to Addressee service under 37 CFR 1.10 & 1.8 on the date indicated above and is addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450:

Fee Transmittal

Transmittal Letter

IDS Statement

IDS Form 1449


Copy of International Search Report

Copy of Supplemental Information Disclosure Citation (2)

Return Postcard

Linda Haley
(Typed or printed name of person mailing paper or fee)

Linda Haley
(Signature of person mailing paper or fee)



TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
2927/1A

Re Application Of: Chandrakumar, et. al.

Serial No.
10/657,570

Filing Date
September 8, 2003

Examiner
Not Assigned

Group Art Unit
Not Assigned

Title: Meta-Substituted Phenylene Sulphonamide Derivatives

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Fee Transmittal, IDS Statement, IDS Form 1449, Copy of International Search Report, Copy of Supplemental Information Disclosure Citation (2), and Return Postcard

in the above identified application.

- No additional fee is required.
- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 19-1025 as described below.
 - Charge the amount of \$180.00
 - Credit any overpayment.
 - Charge any additional fee required.

Signature

Rachel A. Polster
47,004

Dated: December 11, 2003

I certify that this document and fee is being deposited on 12/11/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Linda Haley
Signature of Person Mailing Correspondence

Linda Haley

Typed or Printed Name of Person Mailing Correspondence

CC:



Case 2927/1A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:)
Chandrakumar, et. al.) GROUP ART UNIT: Not Assigned
)
SERIAL NO: 10/657,570) EXAMINER: Not Assigned
)
FILED: September 8, 2003) DATE: December 11, 2003

TITLE: Meta-Substituted Phenylene Sulphonamide Derivatives

Commissioner of Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith Form PTO 1449. Applicants also submit a copy of the International Search Report issued in the corresponding PCT application showing the relevance of this document. Applicants direct the Examiner to the related application(s) for documents previously submitted: specifically, 09/141,547 and 08/824,626. Applicants respectfully request that the examiner consider and enter the documents cited on the enclosed Form PTO 1449 into the file of the above-identified application..

Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.


Please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

12/17/2003 JBALINAN 00000101 191025 10657570
01 FC:1806 180.00 DA

Respectfully submitted,


Rachel A. Polster
Registration No. 47,004
(314) 274-7354 (St. Louis)

Pharmacia Corporation
Global Patent Department
P. O. Box 1027
St. Louis, MO 63006




FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO: 2927/1A	APPLICATION NO.: 10/657,570
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Chandrakumar, et. al.	
(Use several sheets if necessary)		Filed: 9/8/03	Group: Not Assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 2927/1A	APPLICATION NO.: 10/657,570
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INVENTOR: Chandrakumar, et. al.	
(Use several sheets if necessary)	Filed: 9/8/03	Group: Not Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with the citation.	



Information Disclosure Citation for Patent Application

Applicants Copy

Sheet # 1

Attorney Docket No. 2927	Serial Number 08/824,626
Applicant Chandrakumar et al.	
Filing Date 03/27/97	Group Unkn wn

U.S. Patent Documents

Exmnr Init	Seq	Document Number	Issue Date	Name	Class	Sub Class	Filing Date

Foreign Patent Documents

Exmnr Init	Seq	Document Number	Publication Date	Country	Class	Sub Class	Translation
<i>SJY</i> <i>SJY</i> <i>SJY</i>	B1 B2 B3	WO 95/32710 0 478 328 A1 0 478 363 A2	12/07/95 04/01/92 04/01/92	PCT EPO EPO	A61K C07C C07D	31/18 271/22 211/22	

Other Documents (including Author, Title, Date, Pertinent Pages, Etc.)

Exmnr Init	Seq	Author	Title, Publication, Relevant Pages, Date and Place of Publication

Examiner

ASW

Date Considered

5/12/98

Information Disclosure
Citation for Patent Application

11/11/1998
 COPY

Sheet # 1

SEARLE



Attorney Docket No. 2927/1	Serial Number 09/141,547
<i>Applicant</i> Chandrakumar et al.	
Filing Date 08/28/98	Group Unknown

U.S. Patent Documents

Exmnr Init	Seq	Document Number	Issue Date	Name	Class	Sub Class	Filing Date

Foreign Patent Documents

Exmnr Init	Seq	Document Number	Publication Date	Country	Class	Sub Class	Translation
SM	B1	FR 2 456 731 A	12/12/80	France	C07C	129/12	Y
SM	B2	EP 0 222 608 A	05/20/87	European	C07C	129/12	N
SM	B3	WO 92/08464	05/29/92	PCT	A61K	31/55	N
SM	B4	WO 95/32710	12/07/95	PCT	A61K	31/18	N
SM	B5	0 478 328 A1	04/01/92	EPO	C07C	271/22	N
SM	B6	0 478 363 A2	04/01/92	EPO	C07D	211/22	N

Other Documents (including Author, Title, Date, Pertinent Pages, Etc.)

Exmnr Init	Seq	Author	Title, Publication, Relevant Pages, Date and Place of Publication
SM	C1	Fisher et al.	"Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an 'Arginyl-Glycyl-Aspartyl' (RGD)-Containing Protein", <i>Endocrinology</i> , Vol. 132, p. 1411-1413 (1993)
SM	C2	Brooks et al.	"Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis" <i>Science</i> , Vol. 264, pp. 569-571 (1994)
SM	C3	Brooks et al.	"Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels" <i>Cell</i> , Vol. 79, pp. 1157-1164. (1994)
SM	C4	Seftor, et al.	"Role of the $\alpha_v\beta_3$ Integrin in Human Melanoma Cell Invasion", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561 (1992)

Examiner

ASW/J

Date Considered

7/26/99

2927AR/3